A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

2020 ◽  
Author(s):  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Phase Ii Study

Phase II study of cyclophosphamide, interferon-α and betamethasone (CIB) as induction therapy for patients 60–75 years of age with multiple myeloma stages II and III

2003 ◽  
Vol 4 (4) ◽  
pp. 248-252 ◽  
Author(s):  
Jeanette Lundin ◽  
Anders Österborg ◽  
Magnus Björkholm ◽  
Bo Björkstrand ◽  
Fredrik Celsing ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study ◽  
Interferon Α

scholarly journals Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results

Neoplasma ◽  
2012 ◽  
Vol 59 (04) ◽  
pp. 440-449 ◽  
Author(s):  
L. ZAHRADOVA ◽  
K. MOLLOVA ◽  
D. OCADLIKOVA ◽  
L. KOVAROVA ◽  
Z. ADAM ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dendritic Cell ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Efficacy And Safety ◽  
Study Results ◽  
Id Protein

scholarly journals Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

Haematologica ◽  
2019 ◽  
Vol 104 (11) ◽  
pp. 2265-2273 ◽  
Author(s):  
Ruth Wester ◽  
Bronno van der Holt ◽  
Emelie Asselbergs ◽  
Sonja Zweegman ◽  
Marie Jose Kersten ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document